HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $52 to $55.
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $52 to $55.